Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...

Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased ...

A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...

Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering ...

Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...